Category Archives: Hypertension

Februarys a great time to focus on your heart. Let's start with your diet. Februarys a great time to focus on your heart Continue reading →

A new discovery by researchers from Ben-Gurion University of the Negev (BGU) and its affiliated Soroka University Medical Center shows that medical cannabis may reduce blood pressure in older adults. The study, published in the European Journal of Internal Medicine, is the first of its kind to focus on the effect of cannabis on blood pressure, heart rate and metabolic parameters in adults 60 and above with hypertension. Older adults are the fastest growing group of medical cannabis users, yet evidence on cardiovascular safety for this population is scarce, says Dr. Continue reading →

According to a new consensus document from European cardiologists, gynecologists, and endocrinologists, doctors should make much stronger efforts to detect high blood pressure in middle-aged women. The study authors said that high blood pressure in women is often written off as either stress or menopausal symptoms, both by their doctors and by the women themselves. When the diagnosis is overlooked, however, it can cause women to delay treatment, putting them at greater risk for conditions like heart failure and stroke. Continue reading →

Global Hypertension Management Devices Market: Overview Hypertension is a key risk factor for cardiovascular diseases and continues to be a major cause of global morbidity and mortality. Continue reading →

GLEN CARBON Dr. Julie Steinhauer, OD, FCOVD, owner of Vision For Life, and one of a select group of functional vision doctors in the nation, says those with hypertension, known as high blood pressure, may often suffer from undiagnosed vision issues. Left unchecked hypertension can cause blurriness, double vision or a complete loss in one part of the visual field Continue reading →

Risk of hypertensive disorders of pregnancy linked to trophectoderm biopsy in new study A large single-centre study has found a two-fold higher risk of pregnancy-related hypertension following blastocyst biopsy and frozen transfer than in non-biopsied controls. Continue reading →

India Hypertension Control Initiative (IHCI), a multi-partner initiative led by the Indian Council of Research (ICMR) has been successful in improving blood pressure control rates across four states. Continue reading →

Introduction Hypertension intracerebral hemorrhage (ICH) is associated with high mortality and disability.14 Few effective treatments are available in the several prospective, randomized, controlled, multicenter trials, except for rapid blood-pressure lowering.58 Primary brain injury is mainly caused by mechanical damage to the surrounding tissues inducing by dissection and compression of the hematoma formation within the first few hours after ICH onset.9 Secondary brain injury caused by the physiologic response to the primary brain injury could lead more serious and fatal injury, which plays a key role in the overall prognosis of ICH.9 The preclinical studies have suggested that inhibition of neuroinflammation holds beneficial effect on ICH animals after central nervous system (CNS) injury.2,913 The renin-angiotensin-aldosterone system (RAAS), existing in the cardiovascular system, kidneys and CNS, can influence the outcome of ischemic stroke.1416 Angiotensin (Ang) is a product of the proteolytic cleavage of Ang I by Angiotensin-converting enzyme (ACE) and is the pivotal protein of the RAAS for the regulation of blood pressure.14 Ang can also produce an inflammatory response by binding to type-1 Ang receptors.17 Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are two critical suppressors of the RAAS and widely used as the first-line anti-hypertensive drugs.18 Previous researches have shown that ACEIs/ARBs have multiple neuroprotective effects, such as slowing inflammatory processes, inhibition of fibrinoid necrosis, anti-apoptotic and anti-oxidant effects by the reduction of Ang in the animal models after CNS injury.2,17,1924 However, the role of ACEIs and ARBs in ICH patients with hypertension remains elusive in clinic.25 Herein, the aim of the present study is to evaluate the effect of ACEIs/ARBs on ICH patients with hypertension using a retrospective, single-center data analysis. This retrospective study was approved by the Ethics Committee of the Southwest Hospital, Third Military Medical University (approval no. Continue reading →

SOUTH SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from an analysis determining the validity of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 risk calculator, an abridged version of the REVEAL 2.0 risk calculator, in patients with pulmonary arterial hypertension (PAH), a rapidly progressive disease with no known cure.1,2,3 The analysis showed that REVEAL Lite 2 offers a simplified method of risk assessment using six non-invasive and modifiable variables that may be implemented routinely in daily clinical practiceand can be used in conjunction with REVEAL 2.0, and differentiates patients among low, intermediate and high risk of one-year mortality Continue reading →

INDIANAPOLIS (WISH) Dr. Ashwin Ravichandran at Ascension St. Vincent Hospital in Indianapolis wasnt predicting the future when he first joined a clinical trial for a new way to treat pulmonary hypertension, a type of blood pressure in the lungs now associated with COVID-19 Continue reading →